203 related articles for article (PubMed ID: 18242510)
1. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Iorns E; Turner NC; Elliott R; Syed N; Garrone O; Gasco M; Tutt AN; Crook T; Lord CJ; Ashworth A
Cancer Cell; 2008 Feb; 13(2):91-104. PubMed ID: 18242510
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics.
Swanton C; Downward J
Cancer Cell; 2008 Feb; 13(2):83-5. PubMed ID: 18242507
[TBL] [Abstract][Full Text] [Related]
3. Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells.
Khanal P; Yun HJ; Lim SC; Ahn SG; Yoon HE; Kang KW; Hong R; Choi HS
Oncogene; 2012 Aug; 31(34):3845-56. PubMed ID: 22158035
[TBL] [Abstract][Full Text] [Related]
4. Dissecting resistance to endocrine therapy in breast cancer.
Lord CJ; Iorns E; Ashworth A
Cell Cycle; 2008 Jul; 7(13):1895-8. PubMed ID: 18604164
[TBL] [Abstract][Full Text] [Related]
5. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
6. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
Keeton EK; Brown M
Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
[TBL] [Abstract][Full Text] [Related]
7. CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.
Guen VJ; Gamble C; Flajolet M; Unger S; Thollet A; Ferandin Y; Superti-Furga A; Cohen PA; Meijer L; Colas P
Proc Natl Acad Sci U S A; 2013 Nov; 110(48):19525-30. PubMed ID: 24218572
[TBL] [Abstract][Full Text] [Related]
8. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
[TBL] [Abstract][Full Text] [Related]
9. Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.
McClaine RJ; Marshall AM; Wagh PK; Waltz SE
Neoplasia; 2010 Aug; 12(8):650-8. PubMed ID: 20689759
[TBL] [Abstract][Full Text] [Related]
10. CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells.
Yu JH; Zhong XY; Zhang WG; Wang ZD; Dong Q; Tai S; Li H; Cui YF
Oncol Rep; 2012 Apr; 27(4):1266-76. PubMed ID: 22209942
[TBL] [Abstract][Full Text] [Related]
11. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
Gao A; Sun T; Ma G; Cao J; Hu Q; Chen L; Wang Y; Wang Q; Sun J; Wu R; Wu Q; Zhou J; Liu L; Hu J; Dong JT; Zhu Z
Nat Commun; 2018 Oct; 9(1):4180. PubMed ID: 30301939
[TBL] [Abstract][Full Text] [Related]
12. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
13. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
15. IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
Zhang Y; Wester L; He J; Geiger T; Moerkens M; Siddappa R; Helmijr JA; Timmermans MM; Look MP; van Deurzen CHM; Martens JWM; Pont C; de Graauw M; Danen EHJ; Berns EMJJ; Meerman JHN; Jansen MPHM; van de Water B
Oncogene; 2018 Apr; 37(14):1869-1884. PubMed ID: 29353882
[TBL] [Abstract][Full Text] [Related]
16. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
17. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
[TBL] [Abstract][Full Text] [Related]
18. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
19. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
[TBL] [Abstract][Full Text] [Related]
20. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
